Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vagil Cancer - Overview
Vagil Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vagil Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vagil Cancer - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Bristol-Myers Squibb Co
Chengdu Institute of Biological Products Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Hookipa Pharma Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ology Bioservices Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Perseus Proteomics Inc
Pionyr Immunotherapeutics Inc
Precigen Inc
Privo Technologies Inc
RemeGen Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
SQZ Biotechnologies Co
Suzhou Neupharma Co Ltd
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc
Vagil Cancer - Drug Profiles
adavosertib - Drug Profile
Product Description
Mechanism Of Action
bevacizumab - Drug Profile
Product Description
Mechanism Of Action
bintrafusp alfa - Drug Profile
Product Description
Mechanism Of Action
cisplatin - Drug Profile
Product Description
Mechanism Of Action
decitabine - Drug Profile
Product Description
Mechanism Of Action
disitamab vedotin - Drug Profile
Product Description
Mechanism Of Action
durvalumab - Drug Profile
Product Description
Mechanism Of Action
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
HB-201 - Drug Profile
Product Description
Mechanism Of Action
HB-202 - Drug Profile
Product Description
Mechanism Of Action
HPV-16 E7 - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
M-9241 - Drug Profile
Product Description
Mechanism Of Action
MEDI-0457 - Drug Profile
Product Description
Mechanism Of Action
nivolumab - Drug Profile
Product Description
Mechanism Of Action
NTO-1151 - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
peltopepimut-s - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
PPMX-T002 - Drug Profile
Product Description
Mechanism Of Action
PRGN-2009 - Drug Profile
Product Description
Mechanism Of Action
PRV-211 - Drug Profile
Product Description
Mechanism Of Action
PY-159 - Drug Profile
Product Description
Mechanism Of Action
PY-314 - Drug Profile
Product Description
Mechanism Of Action
RX-208 - Drug Profile
Product Description
Mechanism Of Action
SCT-1000 - Drug Profile
Product Description
Mechanism Of Action
SQZ-AACs (Oncology) - Drug Profile
Product Description
Mechanism Of Action
SQZ-APCs (Oncology) - Drug Profile
Product Description
Mechanism Of Action
tipapkinogene sovacivec - Drug Profile
Product Description
Mechanism Of Action
TST-005 - Drug Profile
Product Description
Mechanism Of Action
Vagil Cancer - Dormant Projects
Vagil Cancer - Product Development Milestones
Featured News & Press Releases
Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
Jun 17, 2015: GARDASIL9: New HPV vaccine approved in the European Union
Apr 01, 2015: Merck’s HPV Vaccine, GARDASIL 9, now available in Cada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Vaginal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Vaginal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Vaginal Cancer - Pipeline by AstraZeneca Plc, 2022
Vaginal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Vaginal Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Vaginal Cancer - Pipeline by Eisai Co Ltd, 2022
Vaginal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Vaginal Cancer - Pipeline by Gilead Sciences Inc, 2022
Vaginal Cancer - Pipeline by Hookipa Pharma Inc, 2022
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
Vaginal Cancer - Pipeline by Merck & Co Inc, 2022
Vaginal Cancer - Pipeline by Merck KGaA, 2022
Vaginal Cancer - Pipeline by Ology Bioservices Inc, 2022
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Vaginal Cancer - Pipeline by PDS Biotechnology Corp, 2022
Vaginal Cancer - Pipeline by Perseus Proteomics Inc, 2022
Vaginal Cancer - Pipeline by Pionyr Immunotherapeutics Inc, 2022
Vaginal Cancer - Pipeline by Precigen Inc, 2022
Vaginal Cancer - Pipeline by Privo Technologies Inc, 2022
Vaginal Cancer - Pipeline by RemeGen Co Ltd, 2022
Vaginal Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
Vaginal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Vaginal Cancer - Pipeline by Suzhou Neupharma Co Ltd, 2022
Vaginal Cancer - Pipeline by Transcenta Holding Ltd, 2022
Vaginal Cancer - Pipeline by Transgene SA, 2022
Vaginal Cancer - Pipeline by Turnstone Biologics Inc, 2022
Vaginal Cancer - Dormant Projects, 2022